Bartneck et al. reported that CCL2 inhibition in a fibrosis-HCC murine model significantly reduced pathogenic vascularization and tumor volume, while Li et al. observed similar results with a CCR2 antagonist [32,33]. This evidence concerns the gene CCR2 and hepatocellular carcinoma.